QUOTE AND NEWS
Benzinga  3 hrs ago  Comment 
Novartis International AG / Nine new analyses show Novartis' LCZ696 could change course of heart failure for patients[1],[2] . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this...
FierceBiotech  9 hrs ago  Comment 
Novartis continued to build its case for secukinumab (AIN457), an IL-17A inhibitor in development for a range of inflammatory conditions.
newratings.com  Nov 16  Comment 
Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients Novartis International AG / Novartis reports landmark Phase III results for AIN457 (secukinumab) showing...
newratings.com  Nov 15  Comment 
Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients Novartis International AG / Novartis presents ground-breaking Phase III results showing AIN457...
Motley Fool  Nov 14  Comment 
Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.
Benzinga  Nov 12  Comment 
In a report published Wednesday, Stifel analyst Stephen Willey reiterated a Buy rating on Ophthotech Corp (NASDAQ: OPHT), and raised the price target from $58.00 to $59.00. In the report, Stifel noted, “P3 enrollment remains on track and the...
newratings.com  Nov 12  Comment 
Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One Novartis International AG / Novartis and Malaria No More help fulfill malaria treatment goal in Zambia...
FiercePharma  Nov 10  Comment 
Just as the dust is settling after the big rollout of doctor-payment data in the U.S., a new round has made its debut--in Japan. According to The Japan News, the country's top 10 drugmakers shelled out 190 billion yen ($1.66 billion) to doctors in...
Motley Fool  Nov 10  Comment 
Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.
newratings.com  Nov 10  Comment 
Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014 Novartis International AG / Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki